Just wrapped up two incredible days at the ERS Spring Meeting, planning for the Amsterdam conference. Excited about the opportunities for ECM through the NEXT Programme and engaging ILD sessions! #ERS2025 #Amsterdam #respisbest #ILD

FIBRONEER-IPF results now online at NEJM!!! Nerandomilast slowed FVC decline at 52 weeks: −114.7 ml (18 mg BID) vs −183.5 ml (placebo) Difference: +68.8 ml (p<0.001) Benefit seen with and without background antifibrotics. #ATS2025

Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team nejm.org/doi/full/10.10…

When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo in Progressive Pulmonary Fibrosis patients on antifibrotics or untreated. 👏🏼 Drs Maher, Martinez & #FibroneerILD team!! nejm.org/doi/full/10.10…

🚨 Closing this week! 🚨 Submit your late-breaking abstracts for the #ERSCongress 2025 (27 Sept – 1 Oct). Deadline: 30 May, 2025. Find out more and submit: bit.ly/3vL7gYY

My husband got COVID a week after I gave birth to my son this January. Neither myself nor the newborn got it from him despite extensive contact before he tested himself. I was happy to have received my COVID booster during pregnancy. I am sad that others will lose that option.

Starting in few hours! Join us

Just wrapped up an incredible 5-day ILD preceptorship course in Exeter. Honoured to host 11 brilliant delegates from Argentina — a week of inspiring talks, MDT discussions & deep dives into every corner of ILD care. Grateful, energised, and ready for more! #ILD #curePF

📢ILD-IN Conference bursary deadline has been extended until 25th July! 📢The conference abstract deadline has also been extended until 4th August. All ILD related research, service improvements, audits etc welcome for consideration. ild-in.org.uk/conference/

10 years of ILD-IN We’ll have great speakers, the latest updates, and memorabilia from the past to celebrate. Not-to-miss event for the ILD community #curePF #ILD

channel.ersnet.org/channel-31-cof… Watch the last coffee talk episode. Cormac McCarthy and Nishant Gupta discuss how diffuse cystic lung diseases (DCLDs) differ from typical fibroinflammatory interstitial lung diseases.

📢 Save the date! Join us on 10 Sept 2025 for an #ILDIN webinar with Phil Molyneaux “From Calm to Crisis: ILD Acute Exacerbations” ➡️ For ILD-IN members. Registration info coming soon via email. #ILD #ERS #LungHealth

From 1 September, all severely immunosuppressed adults aged 18 years and over will be able to get the shingles vaccine from their GP. The vaccine significantly reduces the chance of developing shingles – protecting thousands more people most at risk. ℹ️ england.nhs.uk/2025/08/shingl…

New Guidelines published in the European Respiratory Journal access it here: publications.ersnet.org/content/erj/ea… ERS publications

Reminder to ILD-IN members/partners. The 1st in our webinar series takes place tomorrow night! From Calm to Crisis: ILD Acute Exacerbations 🗓️ 10 Sept 2025 - 8-9pm 🎙️ Prof. Phil Molyneaux Learn about recognition, management & new research on one of ILD’s toughest challenges.

As it becomes more difficult to breathe, the energy used in order to get air into the lungs can result in fatigue, low mood, & weight loss. Eating becomes more difficult. Standing up from a sitting position can feel like a workout. PF affects more than just your lungs 🥺

This will kill people

People don’t realize how safe and effective acetaminophen is for pain and fever. By scaring people away from Tylenol, fevers will either go untreated (dangerous, especially for young children and fetuses) or NSAIDs will take its place, which carry much more significant side

Our second session of the day is up and running. We have committee members Doria and Katie chairing the session. Maria Kokosi is informing our delegates of the latest advances and innovations in the world of ILD. New pharmaceutical approaches are the order of the day!

And with that, ILD-IN conference 2025 is over! Thank you to all our speakers, delegates and exhibitors. We hope everyone has had a fantastic couple of days. Attendees will receive a feedback form and save the date for next year, we hope to see you back in Birmingham in 2026!